Abstract: Retinitis pigmentosa (RP) is a group of heterogeneous inherited retinal degenerative disorders characterized by progressive rod and cone dysfunction and ensuing photoreceptor loss. Many patients suffer from legal blindness by their 40s or 50s. Artificial vision is considered once patients have lost all vision to the point of bare light perception or no light perception. The Argus II retinal prosthesis system is one such artificial vision device approved for patients with RP. This review focuses on the factors important for patient selection. Careful pre-operative screening, counseling, and management of patient expectations are critical for the successful implantation and visual rehabilitation of patients with the Argus II device.
True papilledema or pseudopapilledema? Differentiating between these entities in children based on noninvasive imaging would be greatly preferable over an invasive neurological examination – the current gold standard. The authors of a recent study investigated whether the SPECTRALIS® MultiColor Module is helpful to make this distinction. Taking MultiColor images from the optic nerve head of 20 consecutive patients delivered very promising results.
Dr. Robert N. Weinreb
I welcome you to the International Glaucoma Review (IGR) online.
As usual, the IGR will provide you with high quality glaucoma content including the Comments in the Editor’s Selection, the Dialogue, Opinion, and news from the WGA, meeting reports, etc. With this new format, you will be able to quickly navigate the content online and obtain the information that is of interest. If desired, you also will be able to obtain more details via direct links (articles, abstracts, database, etc.).
With plans well underway for SOE2019 we are pleased to share our confirmed Key note Lectures which cover the breadth of Ophthalmology and are just some of the jewels in our treasure chest that is our Scientific programme. We look forward to welcoming you to the next European Congress of Ophthalmology in Nice from 13–16 June 2019.
Along with a selection of the best lecturers in the world who will share every conceivable aspect of ophthalmology, our YO Committee will provide specific YO activities and sessions and the most recent state-of-art equipment and devices will be on display at the exhibition.
We look forward to seeing you in Nice in 2019!
Jan Tjeerd de Faber
The WGA aspires in becoming the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. In becoming a knowledge platform, the association offers access to the Educational Portal that includes recorded sessions from past WGC’s.
Click below to watch the recorded sessions of our past Congresses. WGC-2013 and WGC-2015 content is available for all. The sessions recorded during the 7th WGC will only be available for registered participants and will be released on a monthly basis via the different WGA media channels.
WGC-2017 content is only available to WGC-2017 attendees. WGA will share several WGC-2017 sessions the upcoming year via WGA media channels. Do not miss out and subscribe to the WGA newsletter!
Many patients inquire about the use of marijuana for their uncontrolled glaucoma, especially in the setting of increased legalization in many states. In this article, Dr. Graul discusses various limitations of this Schedule I drug for long-term treatment of glaucoma, including its short duration of action, cost, ocular side effects, general health risks, and high potential for abuse.
BY THOMAS A. GRAUL, MD
n recent years, retinal injuries caused by laser pointers have increased significantly - especially among young people. What are the preferred imaging modalities to identify these injuries? What difficulties can be expected? What role does OCT play? In his video presentation, Ethan Priel, Director of Ophthalmology Dept., MOR Institute Israel, discusses the topic comprehensively.
What has been your most successful collaboration?
Without a doubt, working with Don Budenz; we’ve had enormously successful collaborations dating back more than 20 years. I owe the majority of my H-index to Don’s relentless hard work in research. We started working together in 1996 with the first use of amniotic membrane transplantation in glaucoma surgery, initially in rabbits and subsequently in a human randomized controlled trial. After that, we collaborated – or rather, Don did all the work and I helped! – in the ABC study (which we co-chaired), the Tema Eye Survey and the Tema Eye Survey II. In between, we were both investigators in the TVT and PTVT studies. Parenthetically (and outside of Ophthalmology), Don’s wife, Sue, rescued my 19-year-old son from a crack house in Chapel Hill!
Navigating from a young ophthalmologist to a prominent leader in eye care is no easy task. The ICO is here to help. We are proud to announce the launch of a new program that will kick off at [www.icoph.org/woc2018]WOC2018 in Barcelona this June: Emerging International Leaders Initiative.
by Mark Gallardo, MD
Mark Gallardo, MD, discusses strategies to determine which microinvasive glaucoma surgery (MIGS) device is the best fit for a specific patient. During his presentation, Dr. Gallardo also shares his personal data and advice on using the iStent Trabecular Micro-Bypass Stent (Glaukos).
WASHINGTON — For patients with highly aberrated corneas due to pellucid marginal degeneration, penetrating keratoplasty or previous refractive surgery, toric lenses can have optimal results, according to a speaker here.
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.